ライフサイエンスコーパス: cardiac failure

1 e to exacerbation of chronic lung disease or cardiac failure).

2 causal relationship between osimertinib and cardiac failure.

3 to pressure overload-induced hypertrophy and cardiac failure.

4 , pulmonary vascular disease, and associated cardiac failure.

5 red cardiac transplantation and four died of cardiac failure.

6 tivated and can depress function, leading to cardiac failure.

7 new therapeutic option against post-infarct cardiac failure.

8 provides a plausible molecular mechanism for cardiac failure.

9 leading to impaired ventricular function and cardiac failure.

10 nts one of the most common causes leading to cardiac failure.

11 d nature of the stress on the development of cardiac failure.

12 culatory support in patients with refractory cardiac failure.

13 rt is presented for patients with refractory cardiac failure.

14 blood cell transfusions to avoid death from cardiac failure.

15 rches, aortic arch arteries, and no signs of cardiac failure.

16 unction are common to virtually all forms of cardiac failure.

17 minent death from irreversible biventricular cardiac failure.

18 key role in the pathogenesis of DOX-induced cardiac failure.

19 ents develop cardiomyopathy, and many die of cardiac failure.

20 ted with LV dilatation, indicating incipient cardiac failure.

21 and hypertension is the most common cause of cardiac failure.

22 toxemia, myocardial cytokine production, and cardiac failure.

23 g in premature death from respiratory and/or cardiac failure.

24 competent, and this value was not changed by cardiac failure.

25 ost commonly related to iatrogenic causes or cardiac failure.

26 s die in utero at midgestation with signs of cardiac failure.

27 variant had 2 children die in childhood from cardiac failure.

28 37 patients subsequently developed new-onset cardiac failure.

29 melaena, and evidence of hepatic disease or cardiac failure.

30 heart; each contributes to the evolution of cardiac failure.

31 en and 12 men undergoing transplantation for cardiac failure.

32 and real decay are systematically altered by cardiac failure.

33 rtrophy can proceed by unknown mechanisms to cardiac failure.

34 m of the ventricular chambers and consequent cardiac failure.

35 rage 50% of the left ventricle, and produced cardiac failure.

36 One patient died of anthracycline-induced cardiac failure.

37 , including obesity, insulin resistance, and cardiac failure.

38 ve distal muscles and causes respiratory and cardiac failure.

39 re is no effective treatment for DMD-related cardiac failure.

40 acute myocardial haemorrhage and subsequent cardiac failure.

41 d in children with refractory respiratory or cardiac failure.

42 n for patients suffering from respiratory or cardiac failure.

43 ardioprotective gene changes and resulted in cardiac failure.

44 and peripheral hemorrhage, characteristic of cardiac failure.

45 lifesaving option for patients with terminal cardiac failure.

46 cumulation, ventricular stretch and possibly cardiac failure.

47 rculatory support (MCS) for the treatment of cardiac failure.

48 ffering a potential therapeutic approach for cardiac failure.

49 hest pain, hemoptysis, clubbing, or signs of cardiac failure.

50 hest pain, hemoptysis, clubbing, or signs of cardiac failure.

51 reduced both inflammation and biomarkers of cardiac failure.

52 cts various pathological pathways related to cardiac failure.

53 that TRF2 is a key player in DMD-associated cardiac failure.

54 n culminating in death due to respiratory or cardiac failure.

55 s to premature death from respiratory and/or cardiac failure.

56 vinculin can also provoke HCM, causing acute cardiac failure.

57 otic reorganization that eventually leads to cardiac failure.

58 umans, and is upregulated by hypertrophy and cardiac failure.

59 LVEF remained stable with no new arrhythmias/cardiac failure.

60 d Gas signaling and thereby protects against cardiac failure.

61 transition from compensatory hypertrophy to cardiac failure.

62 ife, she developed cardiomegaly and signs of cardiac failure.

63 2 may increase susceptibility to DOX-induced cardiac failure.

64 yocyte apoptosis and susceptibility to overt cardiac failure.

65 d a duplication of chromosome 6p and died of cardiac failure.

66 models of acute diseases such as kidney and cardiac failure.

67 0.35 ng/mL) (p = .14) or those patients with cardiac failure (0.21 ng/mL).

68 e, 2 patients died; 1 from stroke and 1 from cardiac failure (30-day mortality: 7.4%).

69 rred through week 24 were anaemia (10 [5%]), cardiac failure (5 [2%]), pyrexia (4 [2%]), and pneumoni

70 bits HIF-1alpha synthesis, resulted in rapid cardiac failure after TAC.

71 tudy, 3 died (from sepsis, tuberculosis, and cardiac failure, all in patients who received 100 mg gol

72 thostimulation may worsen the progression of cardiac failure, although the nature and mechanisms of s

73 c cardiomyopathy (HCM) is a leading cause of cardiac failure among individuals under 35.

74 ients in the abiraterone-prednisone group (1 cardiac failure and 1 cardiac arrest, 1 mesenteric arter

75 Obesity-related HFpEF is a genuine form of cardiac failure and a clinically relevant phenotype that

76 ages for the full cardiac cycle in dogs with cardiac failure and a left bundle conduction delay.

77 nic lethal, with death at mid-gestation from cardiac failure and a unique constellation of developmen

78 nal sodium and water retention, particularly cardiac failure and cirrhosis, have been suggested to ha

79 Snrk in cardiomyocytes (Snrk cmcKO) leads to cardiac failure and death by 8 to 10 months.

80 ly debilitating DCM that ultimately leads to cardiac failure and death, whereas autosomal dominant mu

81 nopus lead to valve defects and, ultimately, cardiac failure and death.

82 y and are associated with the development of cardiac failure and death.

83 Ndufs6(gt/gt) mice are at increased risk of cardiac failure and death.

84 febrile illness-induced neurodegeneration or cardiac failure and early death.

85 roper myocardial development with subsequent cardiac failure and embryonic demise.

86 erous endocrine diseases, hepatic cirrhosis, cardiac failure and even death.

87 sociated with disease progression leading to cardiac failure and fibrosis.

88 n their cirrhotic liver who developed severe cardiac failure and have iron deposits in the heart, des

89 It is up-regulated in cardiac failure and hypertrophy and represses expression

90 However, during cardiac failure and hypertrophy, ANF expression can reap

91 d autonomic neuropathy often with associated cardiac failure and is due to dominantly inherited trans

92 (betaAR) blockade is a standard therapy for cardiac failure and ischemia.

93 mab plus chemotherapy group, one each due to cardiac failure and malignant neoplasm progression in th

94 patients in the ibrutinib-placebo group (n=1 cardiac failure and n=1 COVID-19-related pneumonia).

95 Two deaths were reported (cardiac failure and ovarian carcinoma), neither related

96 ces underlie human medical disorders such as cardiac failure and pulmonary injury.

97 ient zebrafish had skeletal muscle weakness, cardiac failure and small heads.

98 , one patient in the placebo group died from cardiac failure and two had serious infections; no gusel

99 ne-prednisone group (2 pulmonary embolism, 1 cardiac failure) and five (1%) patients in the abiratero

100 d leukaemia, one with pancytopenia and acute cardiac failure) and four patients in the pomalidomide g

101 erwent LT at Mayo Clinic, 4 with high output cardiac failure, and 1 with biliary ischemia.

102 eneration, CV Prevention & Health Promotion, Cardiac Failure, and Cardiomyopathies (1-70).

103 eneration, CV Prevention & Health Promotion, Cardiac Failure, and Cardiomyopathies.

104 may lead to pump failure, as in hypertensive cardiac failure, and could explain features of breast ca

105 es including stroke, coronary heart disease, cardiac failure, and endstage renal disease.

106 4 hypertensive encephalopathy, grade 3 acute cardiac failure, and grade 3 breast pain).

107 myocardium of patients affected by end-stage cardiac failure, and whether these cells can be harveste

108 s infection, steal syndrome, and high-output cardiac failure; and making timely referrals to facilita

109 ons, liver developmental delay, and die from cardiac failure around embryonic day (E) 14.5 pc.

110 times as high in the hearts of patients with cardiac failure as in the normal hearts, whereas labelin

111 heir medium and large arteries and expire of cardiac failure as neonates, while calciphylaxis of CKD

112 esis and suggest a combination of anemia and cardiac failure as the cause of embryonic lethality in t

113 icular failure, ventricular dysfunction, and cardiac failure, as well as the names of specific journa

114 ac hypertrophy at 4 weeks and progressing to cardiac failure at 8 weeks using whole-cell patch-clamp

115 uption of mitochondrial fusion causes lethal cardiac failure at a time corresponding to 3 or 4 cycles

116 rative disease that frequently culminates in cardiac failure at an early age.

117 had clinical progression (eg, admission for cardiac failure, atrial fibrillation, and syncope).

118 day11.5 observed with PBP null mutation was cardiac failure because of noncompaction of the ventricu

119 e effects include electrolyte abnormalities, cardiac failure, bleeding diathesis, and phlebitis.

120 hG alpha h activity is associated with human cardiac failure but that the mechanism differs between i

121 sion of fetal marker genes characteristic of cardiac failure, but no significant hypertrophy at the o

122 Ninety patients had developed cardiac failure by 1 yr of dialysis therapy.

123 ollow-up after normalization is warranted as cardiac failure can recur.

124 n at levels so extreme as to elicit signs of cardiac failure, can be reversed by natural regenerative

125 h cemiplimab (due to autoimmune myocarditis, cardiac failure, cardio-respiratory arrest, cardiopulmon

126 ventions, CVD Prevention & Health Promotion, Cardiac Failure, Cardiomyopathies, Genetics, Omics, & Ti

127 ventions, CVD Prevention & Health Promotion, Cardiac Failure, Cardiomyopathies, Genetics, Omics, & Ti

128 ng sections: Basic & Translational Research, Cardiac Failure, Cardiomyopathies/Myocardial & Pericardi

129 he sections: Basic & Translational Research, Cardiac Failure, Cardiomyopathies/Myocardial & Pericardi

130 he sections: Basic & Translational Research, Cardiac Failure, Cardiomyopathies/Myocardial & Pericardi

131 Increasing the heart rate of the fetus with cardiac failure caused by complete AV block (CAVB) may a

132 Only congestive cardiac failure (CCF) was an independent predictor of si

133 ) were rheumatic heart disease or congestive cardiac failure, chronic obstructive pulmonary disease,

134 ogy of edema as occurs in conditions such as cardiac failure, cirrhosis, and pregnancy.

135 7 g/m(2) in those who subsequently developed cardiac failure compared with 0 g/m(2) among those who d

136 increased risk of myocardial infarction and cardiac failure compared with nondiabetic age-matched in

137 previous medical conditions predisposing to cardiac failure: congestive heart failure (CHF; 6 [27%]

138 reduced synthesis may blunt this pathway in cardiac failure, contributing to dampening of the beta-a

139 ron accumulation in their liver explants and cardiac failure despite the absence of HFE mutations.

140 ular disease (angina, myocardial infarction, cardiac failure, diabetes and peripheral vascular diseas

141 resonance imaging (MRI) agents for cancer or cardiac failure diagnosis and therapy monitoring through

142 sed despite follow-up and treatment, causing cardiac failure, diplegia, and neurogenic bladder.

143 It is therefore possible to attribute cardiac failure directly to particular genes by ruling o

144 ly lethal hyperacute respiratory, renal, and cardiac failure due to increased abdominal pressure.

145 eometry and blocked the development of acute cardiac failure during a dobutamine-mediated stress prot

146 MEF2A knock-out mice develop cardiac failure during the perinatal period with mutant

147 Homozygous mice die at embryonic day 14.5 in cardiac failure, exhibiting abnormalities not seen in NM

148 nolinone derivative used in the treatment of cardiac failure, exhibits immunomodulatory, anti-inflamm

149 a treatment modality for acute pulmonary and cardiac failure following orthotopic liver transplantati

150 one pain (one [1%] vs four [2%]), congestive cardiac failure (four [2%] vs two [1%]), myocardial infa

151 Contraindications such as infection and cardiac failure further add to the number of patients wh

152 vant genetic mouse models of hypertrophy and cardiac failure, Galphaq overexpression and human famili

153 Cardiac failure has a principal underlying aetiology of

154 ongestive heart failure, pulmonary edema, or cardiac failure (hazard ratio for the comparison of the

155 bolic risk prediction scores such as CHADS2 (Cardiac Failure, Hypertension, Age, Diabetes, and Stroke

156 rly, there was an increase in mean CHADS(2) [cardiac failure, hypertension, age, diabetes, stroke (do

157 failure, hepatocellular carcinoma, diabetes, cardiac failure, impotence, and arthritis.

158 ns, and evidence for ECMO in respiratory and cardiac failure in adults as well as potential applicati

159 oxygenation (ECMO) for both respiratory and cardiac failure in adults is evolving rapidly.

160 ygenation (ECMO) is used for respiratory and cardiac failure in children but is complicated by bleedi

161 lead to worsening pulmonary hypertension and cardiac failure in children, and it is frequently lethal

162 Cardiac failure in elderly patients is commonly interpre

163 inhibitor phospholamban (PLN) has prevented cardiac failure in experimental dilated cardiomyopathy a

164 shortening with age could also contribute to cardiac failure in humans, opening the possibility for n

165 aged diseased hearts and the development of cardiac failure in humans.

166 amin D supplementation might protect against cardiac failure in older people but does not appear to p

167 %) in the olaparib plus paclitaxel group and cardiac failure in one patient (<1%) in the placebo plus

168 mon in both cardiac hypertrophy and failure; cardiac failure in particular is associated with a signi

169 the wall 8 days after coronary occlusion and cardiac failure in rats.

170 ne hypertensive heart disease and congestive cardiac failure in the bictegravir group and one unknown

171 w-up (1 of unexplained sudden death and 1 of cardiac failure in the context of septicemia, respective

172 y artery disease is the most common cause of cardiac failure in the Western world, and to date there

173 of the beta(2)AR caused rapidly progressive cardiac failure in this model.

174 d by transaortic constriction and consequent cardiac failure in vivo.

175 These results have implications for cardiac failure in which force-frequency modulation is b

176 Myocarditis is a leading cause of sudden cardiac failure in young adults.

177 athies (HCMs) are the leading cause of acute cardiac failure in young individuals.

178 ys a critical role in the pathophysiology of cardiac failure, including the modulation of neovascular

179 rog/kg per min, i.v.) to conscious dogs with cardiac failure induced by chronic tachycardia pacing.

180 Cardiac failure is a frequent cause of death in the agin

181 Cardiac failure is a major cause of death in patients wi

182 For example, cardiac failure is a predominant cause of death in neona

183 Cardiac failure is characterised by the loss of cardiomy

184 editary hemorrhagic telangiectasia (HHT) and cardiac failure is liver transplant.

185 m shift for the treatment of respiratory and cardiac failure is tempered by a need for evidence to su

186 Cardiac failure is the most common cause of mortality in

187 Acute cardiac failure may also be a cause of epileptic sudden

188 Patients presented with cardiac failure (median age, 75 [range, 59-90] years).

189 plain the ineffectiveness of nesiritide as a cardiac failure medication.

190 for vitamin D compared with no vitamin D for cardiac failure, MI, and stroke were 0.75 (0.58, 0.97),

191 e placebo or control for on-study events for cardiac failure, MI, and stroke were 0.82 (0.58, 1.15),

192 ed whether vitamin D supplementation reduces cardiac failure, myocardial infarction (MI), and stroke

193 MI, diabetes mellitus, treated hypertension, cardiac failure, myocardial infarction, health insurance

194 lational Research, Biomarkers (NEW section), Cardiac Failure & Myocarditis, Cardiomyopathies & Geneti

195 ng sections: Basic & Translational Research, Cardiac Failure & Myocarditis, Cardiomyopathies & Geneti

196 ng sections: Basic & Translational Research, Cardiac Failure & Myocarditis, Cardiomyopathies & Geneti

197 ng sections: Basic & Translational Research, Cardiac Failure & Myocarditis, Cardiomyopathies/Congenit

198 ons: Aorta; Basic and Translational Science; Cardiac Failure, Myocarditis, and Pericarditis; Cardiomy

199 ide and dexamethasone group (cardiac arrest, cardiac failure, myocarditis, large intestine perforatio

200 ) and of these 80(65%) were symptomatic (eg, cardiac failure n = 39, 31%; thrombocytopenia n = 12, 10

201 d to secondary sclerosing cholangitis (n=1), cardiac failure (n=1), and sepsis (n=3).

202 , and two were considered treatment-related (cardiac failure [n=1] in the buparlisib group and unknow

203 sepsis [n=2], septic shock [n=1], congestive cardiac failure [n=1], and unknown cause [n=1]) versus o

204 rdiac events: death, recurrence of IE, acute cardiac failure, nonscheduled hospitalization for cardio

205 Cardiac failure occurs when the heart fails to adapt to

206 an important mechanism in the development of cardiac failure of either ischemic or nonischemic origin

207 ion for saving lives of those with end-stage cardiac failure, often faces complications from acute al

208 ived the anti-CD3 rIT died from pneumonia or cardiac failure on days 15 and 23.

209 ung infection (three [1%] patients vs none), cardiac failure (one [<1%] vs one [<1%]), and colitis (t

210 -release syndrome (one attributed to grade 5 cardiac failure); one had fatal respiratory failure.

211 in patients who present with recent onset of cardiac failure or arrhythmia.

212 2.5 (10.1) years, and the mean CHA2DS2-VASc (cardiac failure or dysfunction, hypertension, age >/=75

213 b enrolled patients with AF, a CHA2DS2-VASc (cardiac failure or dysfunction, hypertension, age 65-74

214 The CHA2DS2-VASc (cardiac failure or dysfunction, hypertension, age 65-74

215 est imaging, which is not fully explained by cardiac failure or fluid overload.

216 For example, in patients with cardiac failure or liver disease and in pregnant women,

217 No apparent cases of cardiac failure or severe edema occurred.

218 74, 95% CI 5.27 to 14.77), having congestive cardiac failure (OR 1.72, 95% CI 1.18 to 2.50), chronic

219 en cardiac output is low (e.g. in low output cardiac failure) or high (e.g. cirrhosis or pregnancy).

220 he increased risk for myocardial infarction, cardiac failure, or stroke, which are the most common ca

221 athophysiology of heart failure, whether the cardiac failure originates from ischaemic injury or syst

222 rocephalus were risk factors for both severe cardiac failure (p = 0.01 and p = 0.04, respectively) an

223 In disorders such as cardiac failure, PDE5A upregulation may contribute to a

224 treatment by the investigators (one each of cardiac failure, peritonitis, pneumonia, sepsis, cerebro

225 dex and fractional shortening and subsequent cardiac failure persisted after adjusting for baseline a

226 one patient receiving ibrutinib-venetoclax (cardiac failure, pneumonia, and sinus node dysfunction)

227 NF-ATc null mutant mice die in utero of cardiac failure, precluding analysis of the role of NF-A

228 y (MCA) "pseudofeeders" were correlated with cardiac failure, pulmonary hypertension, and encephaloma

229 able physicians to treat patients with acute cardiac failure refractory to conventional therapy.

230 linical trial program (n = 1,142), including cardiac failure-related adverse events and left ventricu

231 or's global safety database was analyzed for cardiac failure-related adverse events, and a literature

232 state of hypertensive load to that of overt cardiac failure remain largely unknown.

233 hemical test abnormalities may be related to cardiac failure, resulting from intrinsic liver disease,

234 We assess the cardiac failure risk in patients receiving osimertinib b

235 nt), three grade 2 treatment-related events (cardiac failure, sarcoidosis, and foot fracture, all in

236 Cardiac failure, shock, atrioventricular block and atria

237 tly licensed for hypertension and congestive cardiac failure, showed neuroprotective and myeloprotect

238 ally ill patients with acute respiratory and cardiac failure supported with extracorporeal membrane o

239 rably attenuates hemodynamic derangements of cardiac failure that develop during exercise in individu

240 ut heart failure (HF) is an unusual cause of cardiac failure that has not been well-characterized.

241 he ventricular myocardium triggered signs of cardiac failure that were not observed after partial ven

242 After the documentation of cardiac failure, the unaffected myocytes were enzymatica

243 l remodeling during the early progression to cardiac failure through the release of reactive oxygen s

244 y and secondary cholangitis, and right-sided cardiac failure to name a few.

245 rial fibrillation (two [2%]), and congestive cardiac failure (two [2%]).

246 a levels displayed substantial resistance to cardiac failure upon pressure overload.

247 Survival in moribund patients with cardiac failure was 48% in 105 children and 33% in 31 ad

248 Thus, cardiac failure was associated with decreased myocardial

249 ative incidence of the composite category of cardiac failure was higher in the dutasteride group than

250 imilar between groups except that congestive cardiac failure was more common in the syncope group.

251 Cardiac failure was noted to have the highest incidence

252 in renin-dependent hypertension and chronic cardiac failure when circulating Ang II is elevated.

253 CV 30/87-infected pigs developed acute fatal cardiac failure, whereas the rest of the pigs were overt

254 However, it is often associated with cardiac failure, which once manifests carries a poor pro

255 cardiac arrhythmia, metabolic acidosis, and cardiac failure, which resulted in death.

256 iatric disorders as well as the treatment of cardiac failure with beta blockers.